Stage 3 COPD Prognosis

Stage 3 Chronic Obstructive Pulmonary Disease (COPD) Prognosis

COPD is a progressive disease that typically increases in severity over time. It is an irreversible disorder for which there is currently no cure. However, there are measures that one can take for a better quality of life. Although this is a dire prognosis, there are ways to combat the disease, and the first step is understanding the progression of COPD in order to understand stage 3 COPD prognosis.

The disorder starts in stage 1, with mild symptoms:

-Chronic coughing

-Sputum: coughing up mucus

-Dyspnea: breathing discomfort

-Shortness of breath

Stages of COPD

Stage 2 of COPD occurs when the symptoms listed above worsen due to the continued decline in lung function. In stage 2 of the disease, a patient will see their pulmonary function test results worsen. They will also notice the additional symptom of chest tightness. Long-acting bronchodilators are often introduced at this point to help alleviate this chest tightness. Long-acting bronchodilators don’t offer immediate relief, however, they do help a person breathe easier over a longer period of time.

Eventually stage 2 COPD will likely progress into stage 3. Stage 3 is when lung function further declines, causing the symptoms listed above to become even worse. Added symptoms at this stage include unintended weight loss and frequent respiratory infections. Additional treatment precautions might be added at this point, including daily medications and participation in a pulmonary rehabilitation class.

In stage 3, exercise is very difficult. Fatigue is increased significantly and quality of life is greatly hindered. Pulmonary function tests (PFT) typically yield results of 30-50 percent at this stage. In stage 1 PFT results are usually 80 percent or more, and in stage 2 results are around 50-80 percent. Stage 3 is when COPD significantly limits the activities that a person can and cannot do, and can be very frustrating for the sufferer.

COPD Treatment Options

For those who have been diagnosed with COPD, the main goals of treatment are: symptom relief, slow down decline in lung function, improve daily lung function, decrease number of acute episodes (aka COPD exacerbations) and improvement in overall quality of life. Many COPD sufferers use supplemental oxygen along with daily medications to manage symptoms. For those with more developed stages of COPD, more serious measures like a lung transplant or reduction might be an option. There is, however, a minimally invasive, alternative treatment that helps most lung disease sufferers. Stem cell therapy might help slow the development of lung disease and even improve it. Rather than managing symptoms like oxygen and medications, stem cell therapy harnesses your body’s natural healing abilities, essentially healing the lung tissue. While stem cell therapy is not a cure, it is an effective treatment that might provide lung disease sufferers with a much greater quality of life.

Of course, if you are looking for an alternative treatment for COPD, then the Lung Institute might be able to help! If you or someone you love would like know more about treatment options, feel free to contact one of our patient care coordinators today or call (800) 729-3065 today.

* All treatments performed at Lung Institute utilize autologous stem cells, meaning those derived from a patient's own body. No fetal or embryonic stem cells are utilized in Lung Institute's procedures. Lung Institute aims to improve patients' quality of life and help them breathe easier through the use of autologous stem cell therapy. To learn more about how stem cells work for lung disease, click here.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

Under current FDA guidelines and regulations 1271.10 and 1271.15, the Lung Institute complies with all necessary requirements for operation. The Lung Institute is firmly in accordance with the conditions set by the FDA for exemption status and conducts itself in full accordance with current guidelines. Any individual who accesses Lung Institute's website for information is encouraged to speak with his or her primary physician for treatment suggestions and conclusive evidence. All information on this site should be used for educational and informational use only.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and stem cell procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.